Congress poster: ISGE 2026 Efficacy of Elinzanetant in VMS Associated With Endocrine Therapy: Subgroup Analyses of the Phase III OASIS-4 Trial (P.389)

Figshare 2026 Open access

Read full text
Authors: Paula Briggs, Fatima Cardoso, Donal J. Brennan, Gilbert G.G. Donders, Nick Panay, Nazanin Haseli Mashhadi, Cecilia Caetano, Maja Francuski, Claudia Haberland, Kaisa Laapas, Christian Seitz, Lineke Zuurman
DOI: 10.71943/bayer.figshare.31211191
Cited by: 0

Abstract

This analysis evaluated the effect of elinzanetant for VMS frequency across BMI and smoking history subgroups in the OASIS-4 study. Elinzantant treatment resulted in numerically greater reductions vs placebo in VMS frequency across all BMI and smoking history subgroups from baseline to week 12.

Fields of Study & Subjects

Menopause: Health Impacts and Treatments Estrogen and related hormone effects Advanced Breast Cancer Therapies

Publication details

Journal / source
Figshare
Publication date
4 March 2026
Language
EN